Join
Live feed
·
INSIDERFilingvia Quantisnow
Apellis Pharmaceuticals Inc. logo

Chief Research and Development Meltzer Leslie was granted 45,220 shares, increasing direct ownership by 73% to 107,024 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
APLS· Apellis Pharmaceuticals Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track APLS (Apellis Pharmaceuticals Inc.) and more on Quantisnow.